November 12-14, 2018
Boston, MA
Book By Friday – Save $600

 

Speakers

Expand/Collapse

Sunny Jain
CEO & Founder
Sun Genomics

Day One

TUESDAY, NOVEMBER 13 2018

16.45 | Producing Precision Probiotics Based on Your Microbiome Signature

Richard Lin
CEO
Thryveinside

Day One

TUESDAY, NOVEMBER 13 2018

17.15 | Personalized Information about your Microbiome to Increase Health

Arjan Narbad
Research Leader
Quadram Institute

Arjan is currently the translational microbiome group leader at the Institute where his research is focused on understanding the role of gut bacteria in health and disease of humans and animals. Arjan’s group has developed probiotic bacteria for reducing the levels of foodborne pathogens such as Campylobacter from the food chain. Arjan has worked on the relationship between gut microbiota and specific gastrointestinal disorders; IBS and Ulcerative Colitis. In collaboration with clinicians at the Norfolk and Norwich University Hospital, his group is actively involved in setting up a bacteriotherapy service for the treatment of Clostridium difficile infections, and are exploring how the exploitation of new technologies could be used to improve the diagnosis of gastrointestinal infections. Arjan has published more than 100 research papers and have filed 9 international patents. Arjan has been appointed a Visiting Professor at Jiangnan University in China and has also recently established a BBSRC funded UK-China joint centre for research on probiotics.

Day One

TUESDAY, NOVEMBER 13 2018

15.15 | Using Scientific Techniques to Design Probiotic Strains with Improved Functionality

Raja Dhir
Co-Founder & Co-CEO
Seed, Inc.

Day One

TUESDAY, NOVEMBER 13 2018

10.30 | Panel Discussion: What are the biggest challenges/opportunities for the nutrition space when reviewing microbiome science for product development?

10.00 | Setting New Industry Standards for Probiotic Discovery & Development

10.30 | Panel Discussion: What Are the Biggest Challenges/Opportunities for the Nutrition Space When Reviewing Microbiome Science for Product Development?

Chris Damman
MD, Program Officer
Bill and Melinda Gates Foundation

Dr. Damman is a board certified gastroenterologist with joint appointments at the Seattle Cancer Care Alliance and University of Washington Medical Center. His education and training include a B.A./M.A. from Wesleyan University in 1998/1999, an M.D from Columbia University in 2006, residency in internal medicine from the University of Washington in 2009, and fellowship in gastroenterology from the University of Washington in 2014.

Day One

TUESDAY, NOVEMBER 13 2018

10.30 | Panel Discussion: What are the biggest challenges/opportunities for the nutrition space when reviewing microbiome science for product development?

09.00 | More than a Crap Shoot…Placing Bets on Enteric Health for Healthy Growth & Development in the Developing World

10.30 | Panel Discussion: What Are the Biggest Challenges/Opportunities for the Nutrition Space When Reviewing Microbiome Science for Product Development?

Ben Goodwin
CEO
Biome Body

Ben has been an entrepreneur and product developer in the health and wellness field for over a decade. In this capacity, he's mpowered other companies to realize their natural product visions and launched my own ventures which have generated substantial traction. Ben's primary passion is to bridge the gap between niche and cutting-edge health trends and mainstream consumer needs. He is extremely motivated to increase the impact and accessibility of products and companies in the health and wellness space. Ben has built three different formulation and fermentation labs, worked closely with dozens of scientists and researchers and built three production facilities from scratch. He's formulated over 30 products from concept to commercialization and beyond, both independently and with a team.

Day One

TUESDAY, NOVEMBER 13 2018

14.45 | The Soil Grows the Garden: Creating Products That Shift the Digestive Eco-System and Facilitate Long-Term Microbiome Change

Aubrey Levitt
Founder & CEO
Body + Eden

Aubrey was the founder of Body + Eden, which has been featured in Oprah Magazine, Elle, Well & Good and Japan Vogue and partnered with brands such as One & Only Resorts, Wallpaper Handmade, and The Tracy Anderson Method. Aubrey is a certified health coach and created a gut health course for the Institute for Integrative Nutrition. She holds a BA from Boston University in Advertising and won an award for best women’s health resource while at Grey Healthcare. She has an MFA in creative nonfiction from The New School in NYC where she has been a guest lecturer on product adoption.

Christopher Reyes
Co-Founder & CSO
Bloom Science, Inc.

Dr. Christopher Reyes is Chief Scientific Officer and co-founder at Bloom Science (www.bloomscience.co), a biotechnology company focused on dramatically improving the lives of patients. Connecting the gut microbiota to diet, metabolism, neural activity and behavior, we are developing effective microbe-based therapeutics to make measurable improvements to outcomes that matter to patients.

Dr. Reyes is a biophysicist and entrepreneur with a passion for creating solutions to improve our health, environment and economic sustainability. He has founded two companies focused on developing therapeutics to address serious medical needs as well as a tech company focused on connecting people to socially conscious commerce solutions.

Dr. Reyes has a Ph.D. in Biophysics at the University of California, San Francisco and B.A. in Molecular and Cell Biology, Biophysics from the University of California, Berkeley.

Day Two

WEDNESDAY, NOVEMBER 14 2018

10.15 | Connecting the Gut Microbiota to Diet, Metabolism, Neural Activity and Behaviour to Develop Effective Microbiota- Based Treatments for Epilepsy and Improved Brain Health

Nalin Siriwardhana
Program Manager - Nutritional Sciences
Church & Dwight

Day Two

WEDNESDAY, NOVEMBER 14 2018

13.15 | Aligning Regulatory Frameworks, Consumer Insights and R&D for Successful Probiotic Claims and Communications

Miguel Freitas
VP, Scientific Affairs
Danone

Miguel is the VP of scientific affairs for Danone in North America, including the Dannon Company and other Danone subsidiaries in the geography, based in White Plains, NY. He serves as a liaison between Danone and the scientific community. He is also responsible for ensuring the integrity of the Danone product portfolio with respect to health attributes and serves as nutrition and scientific spokesperson for convention purposes and media related to brands and category topics.

Lihi Segal
CEO
DayTwo

Lihi Segal co-founded DayTwo in 2015 to bring personalized health solutions based on the gut microbiome into the consumer mainstream. She is experienced in leading business and financial operations having been COO and CFO of Sisense, a provider of business intelligence and analytics software, before starting DayTwo. For more than fifteen years prior to that she has held senior roles in a number of businesses, from startups to large public enterprises. She is a certified Lawyer, has an LLB from the Tel-Aviv University and an MBA from Northwestern University, USA.

Day One

TUESDAY, NOVEMBER 13 2018

16.15 | Machine Learning in the Microbiome: Providing Predictable Personalized Nutrition based on Your Gut

Eric McLaughlin, MD
Chief Medical Officer
Elite Medical Center

Dr. Eric McLaughlin is the Medical Director at Elite Care, a 24-hour, full-service emergency room. Dr. McLaughlin completed his Bachelors in Science in Accounting from Brigham Young University, Utah. He attended medical school at the New York Medical College followed by Emergency Medicine residency in Toledo, Ohio at the St. Vincent Mercy Medical Center. He was awarded the Humanitarian Award for his leadership and compassion in medical care. Dr. McLaughlin is board certified in Emergency Medicine (ABEM). In 2004, he joined the Greater Houston Emergency Physicians (GHEP); and since then, he has become a partner and serves on the Board of Managers.

Day One

TUESDAY, NOVEMBER 13 2018

12.45 | Rehab After Antibiotic Use

David Kyle
Chief Scientific Officer
Evolve Biosystems

David is a 30-year veteran of biotech, having co-founded a range of successful biotech companies in the fields of nutrition and health, including Martek Biosciences, which was acquired in 2011 for $1.1 Billion. David combines a strong scientific background with significant commercial acumen, has published over 70 scientific articles, edited two books, and is the named inventor on over 80 patents.

Day Two

WEDNESDAY, NOVEMBER 14 2018

09.30 | From Dysbiosis to Recovery in the Infant Gut Microbiome: A New Paradigm in Infant Nutrition

Jonathan Scheiman
Co-Founder & CEO
Fitbiomics

Jonathan is a research fellow at the Wyss Institute for Biologically Inspired Engineering, at Harvard University, where he has worked on transformative sequencing technologies and programmable cellular engineering. Along with George Church he has co-founded FitBiomics, a sports biotechnology startup that is sequencing the microbiome of elite athletes to identify and isolate novel probiotics for applications in performance, recovery, and general health. Having played Division 1 college basketball at St. John’s University and coached inner city public high school basketball, one of Jonathan’s long-term goals is to use sport to inspire the next generation of scientists.

Day Two

WEDNESDAY, NOVEMBER 14 2018

13.45 | Promoting Peak Performance: Identifying and Isolating Novel Probiotics from Athlete Microbiomes

Noah Voreades
Consultant
GenBiome Consulting

Noah has been personally and professionally involved in the microbiome, genomic and personalized health space for the past five years.  Recently, leading strategic, product development, regulatory and R&D engagements with Fortune 100 to emerging growth start-ups. In the microbiome space, projects have ranged from advising Fortune-level biotechs on microbiome investment/pipeline/industry trends in support of recent acquisitions, developing R&D strategy for emerging a microbiome CPG beverage to collaborating with one of the leading global probiotic brands on disease indication expansion options. Previously, Noah was Business Development Manager at Ritter Pharmaceuticals, a late-stage microbiome Rx/GI company developing potentially the first FDA approved treatment for moderate-to-severe lactose intolerance. Noah's microbiome expertise reaches beyond therapeutics and nutraceuticals to diagnostics and sample collection technology in a business development role with Metabiomics. Metabiomics is an early-stage microbiome Dx company with multiple patents in IBD and CRC diagnostic development.

Stefan Jennewein
CEO
Jennewein Biotechnologie

Dr. Stefan Jennewein studied Biochemistry, Pharmacology and Organic Chemistry at the Universities of Sussex (Brighton, UK), Zurich (CH), Tübingen (D) and Cambridge (UK), and at the Ludwig-Maximilians-Universität (Munich, D). Dr. Stefan Jennewein also gained practical experience through his work at Washington State University (Pullman, USA), the company DSM N.V. (Delft, NL), the Technical University of Darmstadt (D), and the Fraunhofer Institute for Molecular Biology and Applied Ecology (Aachen, D). Dr. Stefan Jennewein is the Managing Director for research and development, regulatory issues, and quality management at Jennewein Biotechnologie.

Day Two

WEDNESDAY, NOVEMBER 14 2018

10.00 | Human Milk Oligosaccharides (HMOs) Nature’s Prebiotics for a Healthy Infant Microbiome

Speaker TBC

Metabolon

Day One

TUESDAY, NOVEMBER 13 2018

12.00 | The Essential Ingredients for Decoding the Microbiome with Metabolomics

Kiran Krishnan
Chief Scientific Officer
Microbiome Labs

Kiran Krishnan is a Research Microbiologist and has been involved in the dietary supplement and nutrition market for the past 16 years. He comes from a strict research background having spent several years with hands-on R&D in the fields of molecular medicine and microbiology at the University of Iowa. Mr. Krishnan earned his Bachelor of Science degrees in Microbiology at the University of Iowa; his undergraduate education was followed up with post graduate research and advanced course work in Molecular Biology and Virology. He left University research to establish a Clinical Research Organization where he designed and conducted clinical trials in human nutrition.

Day One

TUESDAY, NOVEMBER 13 2018

14.15 | Modulation and Increasing Diversity of the Human Microbiome by Therapeutic Bacillus Endospores

Alan Murray
CEO
NextFoods

CEO Alan Murray, has been involved with NextFoods from its inception, joining the company from a 30 year career with TetraPak, latterly as CEO of its North American business, and Unilever. He champions Nextfood’s retailer, supplier and investor engagement program.

Susan Mitmesser
VP, Science & Technology
Pharmavite

Susan is responsible for ensuring the scientific integrity of the company’s brands and products, she has a keen appreciation for all that probiotics have to offer. She has a PhD in Nutritional Biochemistry from the University of Nebraska and is an adjunct professor in the Department of Family Medicine at Stony Brook University, NY, USA. She contributes regularly to peer-reviewed, trade, and consumer publications on various aspects of nutrition in adult and pediatric populations.

Day Two

WEDNESDAY, NOVEMBER 14 2018

11.15 | How Microbiome Data Can Complement Other Clinical Endpoints to Aid in Health Improvement

Massimo Mazorati
CEO
ProDigest

Massimo has a master degree in Environmental and Alimentary Biotechnology and is an expert in microbial ecology and analysis of mixed microbial communities. He obtained a PhD on "Microbial ecology of complex environments" awarded by the Italian Society of Microbiology and Biotechnology as the best italian thesis in year 2007. He also gained expertise on gastrointestinal microbiology.

Day Two

WEDNESDAY, NOVEMBER 14 2018

11.45 | Delivery, Survival, Engraftment & Activity of LBPs in the Gastrointestinal Tract

Jose Carlos Garcia-Garcia
Principal Scientist
Procter & Gamble

Day One

TUESDAY, NOVEMBER 13 2018

12.15 | Presentation Title TBC, Please Check Back With Us Soon

Mike Janusz
Principal Scientist
Procter & Gamble

Day One

TUESDAY, NOVEMBER 13 2018

10.30 | Panel Discussion: What are the biggest challenges/opportunities for the nutrition space when reviewing microbiome science for product development?

09.30 | Exploiting Mechanism of Action to Develop Probiotics with Desired Health Benefits

10.30 | Panel Discussion: What Are the Biggest Challenges/Opportunities for the Nutrition Space When Reviewing Microbiome Science for Product Development?